Phaseline

Targets › NSP5

NSP5 (Cytospin-B): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease.

Open in Phaseline: the race on NSP5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Unity Health TorontoPaxlovid
SARS-CoV-2 protease inhibitor
3CL, NSP5Phase 3COVID-19–

Conditions

COVID-19 (1)

Modalities

small molecule (1)

Companies

Unity Health Toronto (1)

Related targets

3CL (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.